|
Clinical pathological feature
|
Control (n = 30)
|
Tracer (n = 30)
|
Drug-load (n = 30)
|
Test value
|
P
|
|---|
|
Average age (year)
|
45.4 ± 7.8
|
47.1 ± 8.3
|
48.4 ± 9.8
|
0.885*
|
0.416
|
|
Tumor location
| | | |
10.258#
|
0.247
|
|
Upper outer quadrant
|
18
|
21
|
26
| | |
|
Lower outer quadrant
|
5
|
3
|
0
| | |
|
Upper inner quadrant
|
3
|
4
|
3
| | |
|
Lower inner quadrant
|
1
|
0
|
1
| | |
|
Central area
|
3
|
2
|
0
| | |
|
Clinical stage
| | | |
2.018#
|
0.732
|
|
I
|
8
|
8
|
6
| | |
|
II
|
18
|
15
|
16
| | |
|
IIIA
|
4
|
7
|
8
| | |
|
Pathological type
| | | |
3.000#
|
0.558
|
|
Infiltrating ductal carcinoma
|
29
|
29
|
29
| | |
|
Mucinous carcinoma
|
1
|
1
|
0
| | |
|
Medullary carcinoma
|
0
|
0
|
1
| | |
|
ER
| | | |
1.348#
|
0.510
|
|
Positive
|
19
|
20
|
23
| | |
|
Negative
|
11
|
10
|
7
| | |
|
PR
| | | |
0.098#
|
0.952
|
|
Positive
|
20
|
19
|
20
| | |
|
Negative
|
10
|
11
|
10
| | |
|
HER-2
| | | |
4.229#
|
0.121
|
|
Positive**
|
3
|
8
|
3
| | |
|
Negative##
|
27
|
22
|
27
| | |
|
Surgical approach
| | | |
4.488#
|
0.344
|
|
Modified radical mastectomy
|
20
|
25
|
18
| | |
|
Endoscopic subcutaneous mammary resection + axillary lymph nodes dissection + reconstruction with implants
|
9
|
4
|
11
| | |
|
Breast-conserving surgery + axillary lymph nodes dissection
|
1
|
1
|
1
| | |
-
ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2, IHC immunohistochemistry
- *F value; #χ
2 value; **IHC (3+) in the first biopsy before surgery; ##IHC (0 ~ 2+) in the first biopsy before surgery
